Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|June 19, 2006
- Applied Clinical Trials-06-20-2006
- Volume 0
- Issue 0
Awards Ceremony
DIA President, Theresa Kane Musser, Executive Director, Development Operations, Rigel Pharmaceuticals, presented the awards
Advertisement
DIA President, Theresa Kane Musser, Executive Director, Development Operations, Rigel Pharmaceuticals, presented the awards, which were handed out in the following order:
Drug Information Journal Awards:
Drug Information Journal Student Award: Radhika Nair, MS, PhD, and Anju Parthan, MS, PhD
The Donald E. Francke Award for Overall Excellence in Journal Publishing: Scott Patterson, PhD, and Marilyn Agin, PhD
The Thomas W. Teal Award: William F. Rosenberger, PhD
The DIA Lifetime Membership:
- Dave Domann, MS, RPh, Senior Director, Healthcare Quality Management, Ortho-McNeil Janssen Scientific Affairs, Titusville, NJ.
The Outstanding Service Award:
- Herng-Der Chern, MD, PhD, Executive Director of Taiwan's Center for Drug Evaluation.
- Martin D. Hynes, III, PhD, Director of Product Research and Development, Eli Lilly and Company.
- Shigeru Kageyama, MD, PhD, Professor of Clinical Pharmacology and Therapeutics at Jikei University School of Medicine.
- Mohammed Razdar Khan, Director, Synergex Consulting, Ontario, Canada.
- Pulok K. Mukherjee, MPharm, PhD, FIC, Acting Director, the School of Natural Product Studies, Jadavpur University, Kolkata, India.
- Gary G. Walker, Associate Director, Global Data Integration Standards, Quintiles.
The First Founders Service Award:
- Michael R. Hamrell, PhD, RAC, editor-in-chief of the Drug Information Journal.
The Distinguished Career Award:
- Harry A. Guess, MD, PhD, who passed away in January 2006, was an active member of the association before serving as DIA President from 1992 to 1993.
Articles in this issue
over 20 years ago
Keynote Address: Making Medicine Meaningfulover 20 years ago
Fighting Fraud and Noncomplianceover 20 years ago
Every Potential Patient Is Preciousover 20 years ago
Considering the Critical Path in Oncology Drug Developmentover 20 years ago
PROs and Drug Labeling Undergo Scrutinyover 20 years ago
SAS Drug Development Adds Genomic-Analysis CapabilitiesAdvertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What Needs to Happen Beyond the Clinical Trial Modernization Act
2
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance
5